Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

This study is testing furmonertinib (at a dose of 160 mg) as the first treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific EGFR gene mutations (exon 19 deletion or L858R). These mutations make lung cancer cells sensitive to EGFR-blocking drugs called third-generation TKIs. **You may be eligible if...** - You are 18 or older with confirmed advanced or metastatic lung cancer (adenocarcinoma type) - Your tumor has an EGFR mutation (exon 19 deletion or L858R) confirmed by local testing - You have not previously received any systemic cancer treatment for your advanced disease - You have at least one measurable tumor lesion on imaging **You may NOT be eligible if...** - You have previously received EGFR-targeting therapy or any other cancer treatment for this advanced disease - Your cancer has spread to the brain in an active, symptomatic way - Your heart function (particularly QTc interval) or organ function does not meet the required thresholds Talk to your doctor to see if this trial is right for you.